ibritumomab tiuxetan

Known as: ibritumomab tiuxetan [Chemical/Ingredient] 
A monoclonal antibody that is used to treat certain types of B-cell non-Hodgkin lymphoma and is being studied in the treatment and detection of other… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
In 2008, we reported favorable 5-year outcomes of nonmyeloablative allogeneic stem cell transplantation after fludarabine… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
A prospective, multicenter, nonrandomized phase 2 trial was conducted to evaluate the efficacy and safety of a single dose of… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2007
Highly Cited
2007
PURPOSE To investigate the incidence of treatment-related myelodysplastic syndrome (t-MDS) and treatment-related acute… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
We conducted a phase 1/2 trial of high-dose 90Y-ibritumomab tiuxetan in combination with high-dose etoposide (VP-16) 40 to 60 mg… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 4
Is this relevant?
Review
2005
Review
2005
Immunoconjugates—monoclonal antibodies (mAbs) coupled to highly toxic agents, including radioisotopes and toxic drugs… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2004
Highly Cited
2004
We previously demonstrated that yttrium-90 (Y-90) ibritumomab tiuxetan (Zevalin) radioimmunotherapy (RIT) was safe and effective… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
PURPOSE Radioimmunotherapy (RIT) with yttrium-90 ((90)Y)-labeled anti-CD20 antibody ((90)Y ibritumomab tiuxetan; Zevalin, IDEC… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
UNLABELLED Ibritumomab tiuxetan is an anti-CD20 murine IgG1 kappa monoclonal antibody (ibritumomab) conjugated to the linker… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2002
Highly Cited
2002
PURPOSE Radioimmunotherapy combines biologic and radiolytic mechanisms to target and destroy tumor cells, thus offering a needed… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Mildly thrombocytopenic patients with relapsed or refractory low-grade non-Hodgkin lymphoma (NHL) have an increased risk of… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 5
Is this relevant?